Overview

S-Equol in Alzheimer's Disease 2 Trial

Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
By doing this study researchers hope to learn if S-equol, a compound that acts like estrogen in the body, causes an increase in mitochondrial activity. Researchers also hope to determine the safety and tolerability of a therapeutic dose of S-equol and whether or not it influences cognition.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Russell Swerdlow
Russell Swerdlow, MD
Collaborator:
Ausio Pharmaceuticals, LLC
Treatments:
Equol